This is a Phase 1 cohort, dose-escalation, dose-expansion study of PRT543 in patients
with advanced cancers who have exhausted available treatment options. The purpose of this
study is to define a safe dose and schedule to be used in subsequent development of
PRT543.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03886831.
Locations matching your search criteria
United States
Pennsylvania
Pittsburgh
University of Pittsburgh Cancer Institute (UPCI)Status: Active
Name Not Available
This is a multicenter, open-label, sequential-cohort, dose-escalation, dose-expansion
Phase 1 study of PRT543 in patients with advanced cancers who have exhausted available
treatment options. Enrollment will take place concurrently into two distinct patient
groups (one for solid tumors/lymphomas and one for hematological malignancies). The study
will consist of 2 parts, a dose escalation part, and once the recommended phase 2 dose
(RP2D) has been determined, a cohort expansion part involving up to ten separate cohorts.
For patients, the study will include a screening phase, a treatment phase, and a post
treatment follow-up phase. An end-of-study visit will be conducted within 30 days after
the last dose of PRT543.
Lead OrganizationPrelude Therapeutics
